Please assess the completion status of the following clinical trial:

Trial Title: A Study of Infliximab in Patients With Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have been diagnosed with sarcoidosis at least 1 year prior to entry into the study~* Patients must have laboratory test diagnosing sarcoidosis prior to screening~* Patients must have a diagnosis of sarcoidosis by chest x- ray~Exclusion Criteria:~* Patients must not have used any investigational drug within 1 month prior to entering the study~* Patients must not have received previous administration of a treatment with any other therapeutic agent targeted at reducing TNF such as pentoxifylline, thalidomide, etanercept, CDP 870, adalimumab, within 3 months prior to screening~* Patients must not have received vaccinations within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).